Cas No.: | 1219168-18-9 |
Chemical Name: | Dorsomorphin Dihydrochloride |
Synonyms: | Dorsomorphin Dihydrochloride;Dorsomorphin 2HCl;6-[4-(2-piperidin-1-ylethoxy)phenyl]-3-pyridin-4-ylpyrazolo[1,5-a]pyrimidine,dihydrochloride;BML-275;Dorsomorphin dihydrochloride (Compound C, BML-275);6-[4-[2-(1-PIPERIDINYL)ETHOXY]PHENYL]-3-(4-PYRIDINYL)-PYRAZOLO[1,5-A]PYRIMIDINE DIHYDROCHLORIDE;BML-275 2HCl;BML275 dihydrochloride;BML-275 dihydrochloride;Compound C dihydrochloride;FD5027;S7306,BML-275,Compound C |
SMILES: | [H]Cl.[H]Cl.C12=C(C3=CC=NC=C3)C=NN1C=C(C4=CC=C(OCCN5CCCCC5)C=C4)C=N2 |
Formula: | C24H25N5O.2[HCl] |
M.Wt: | 472.41008 |
Purity: | 98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | Dorsomorphin dihydrochloride (BML-275 dihydrochloride) is a potent, selective and ATP-competitive AMPK inhibitor, with a Ki of 109±16 nM. |
In Vivo: | Administration of Dorsomorphin over 24 h leads to a 60% increase in total serum iron concentrations. Dorsomorphin treatment is therefore effective in reducing basal levels of hepcidin expression and increasing serum iron concentrations in adult mice[3]. |
In Vitro: | HT1080 cells are treated with 10 μM Dorsomorphin for 2 h under 2DG stress. Immunoblot analysis reveals that phosphorylation levels of the catalytic α subunit of AMPK are increased by exposure of HT1080 cells to 2DG, whereas both basal and 2DG-induced phosphorylation levels are clearly reduced when Dorsomorphin is added. Measurements of cellular kinase activity using an ELISA-based assay system confirmed that Dorsomorphin does reduce the endogenous AMPK activity regardless of cell culture conditions[2]. |